Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Osakasayama-shi, Japan Clinical Trials

A listing of Osakasayama-shi, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (6) clinical trials

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

This study consists of 2 cohorts of the ACM regimen part for Japanese relapsed/refractory AML patients and 1 cohort of the A+7+3 regimen part for Japanese newly diagnosed AML patients. The purpose of this study are as below. To evaluate the safety of DSP-2033 (Alvocidib) in combination with cytarabine/mitoxantrone (ACM ...

Phase

0.0 miles

Learn More »

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

This study is an open-label, multicenter, phase 1 study of SyB C-0501 by continuous daily oral administration in patients with advanced solid tumors, who have previously received anticancer therapy and consists of two parts. Part 1 is a dose escalation study to evaluate tolerability of SyB C-0501 in the patients, ...

Phase

0.0 miles

Learn More »

A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Asian Adult Participants With Myeloproliferative Neoplasm

There are 2 parts to this study for which the primary objectives are to evaluate safety and tolerability, including dose-limiting toxicities (DLTs), and pharmacokinetics of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib (Part 2). In Part 2, participants must have been receiving a stable ...

Phase

1.92 miles

Learn More »

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial is composed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of ...

Phase

1.93 miles

Learn More »

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

This study has two parts: dose escalation and dose expansion. The primary objectives are: For Dose Escalation, to assess the safety and tolerability of DS-1205c when combined with gefitinib in the study population and to determine the recommended dose for expansion of DS-1205c when combined with gefitinib in the study ...

Phase

1.93 miles

Learn More »

Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies

The primary objective of the study is to assess the safety, tolerability, and Pharmacokinetics (PK) of REGN2810 in Japanese patients with advanced malignancies. The secondary objective of the study is to assess the immunogenicity of REGN2810.

Phase

5.53 miles

Learn More »